GS-4997

Jefferies maintained its Buy rating on Gilead Sciences, Inc. (NASDAQ: GILD) saying that Wall Street underappreciated the impressiveness of last week's phase II 4997 data and shares don't reflect HIV stability and potential pipeline upside. GS-4997 is being studied in nonalcoholic...